Cleerly today said it has launched its digital care software for heart attack prevention following a $43 million Series B funding round.
New York-based Cleerly’s digital care technology is a non-invasive coronary computed tomography angiography that performs coronary artery phenotyping through artificial intelligence. According to the company, it uses millions of annotated lab images to build more than two dozen algorithms that quantify and characterize the presence, extent, severity and type of coronary artery disease and other cardiovascular diseases.
“Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number one killer – heart disease,” CEO James Min said in a news release. “Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the twenty-first century.”
Cleerly’s Coronary platform measures the comprehensive quantification and characterization of plaque buildup in each of the heart’s arteries to support the identification of plaques that could lead to heart attacks.
The Series B funding round was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors.